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Abstract 
Background: Contraceptive injection is the most common contraception used in 
Indonesia. Among the contraceptive injections, depomedroxy progesterone acetate 
(DMPA) is the most effective method with a pregnancy rate of 0,3 pregnancy in 100 
women annually. Abnormal uterine bleeding (AUB) is a common side effect occurred 
in DMPA users which leads to the discontinuation of contraception. Tranexamic acid 
(TXA) can be used as an alternative therapy for AUB due to DMPA injection, if 
bleeding still occurs after low dose OCP therapy.  
Objective: To explore the effect of TXA on bleeding length for DMPA users with 
AUB who receive low dose Oral Contraceptive Pills(OCP). 
Methods: We performed a double-blind randomized control trial between two groups 
to investigate the effect of TXA in managing AUB in DMPA users who receive low 
dose OCP. This study was performed in dr. Kariadi Hospital Semarang, Indonesia. 
Forty-four subjects were divided into two groups, equally. Group 1 received 250 mg 
TXA four times a day for 5 days and OCP once a day for 28 days, while Group 2 
received placebo four times a day for 5 days and OCP once a day for 28 days. Both 
groups were evaluated for bleeding length during treatment and were analyzed using 
Mann Whitney. 
Results: The mean bleeding length was 5.2±3.62 days and 9.2±6.16 days in group 1 
and 2 respectively. These bleeding lengths were significantly different between both 
groups (p=0.018). The percentage of subjects in whom bleeding was stopped during 
the first week after initial treatment was significantly higher in group 1 than group 2 
(77.3 % VS 45.5 %, p<0.050).  
Conclusion: TXA significantly reduced the bleeding length in DMPA users who use 
OCP. TXA can be used as alternative therapy to enhance the OCP effectivity for AUB 
due to DMPA. 
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INTRODUCTION 
 Contraception program in countries with fast-
growing population will decrease maternal mortality and 
neonatal mortality leading to the achievement of 
Sustainable Developmental Goals (SDG).1,2,3 In fact, 
there are 9 % of unmet need (reproductive women who 
want to delay pregnancy or do not want to be pregnant 
anymore but do not use contraception) with one of the 
main reason was the side effects of contraception, such 
as Abnormal Uterine Bleeding (AUB).4,5 Contraceptive 
injection is the most common contraception used in 
Indonesia which about 32 %.5 Among the contraceptive 
injections, depo medroxyprogesterone acetate (DMPA) is 
the most effective one. Unfortunately, 90% of DMPA 
users experience AUB, and this bleeding will lead to the 
discontinuation of the contraception.6 
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 Abnormal uterine bleeding due to DMPA is 
categorized in AUB-I (Iatrogenic) according to  
International Federation of Gynecology and Obstetrics 
(FIGO) classification.7 The mechanism of the bleeding 
related to use of DMPA is not fully understood. The 
proposed mechanism is continuous endometrial exposure 
to a constant dose of progesterone. The activity of matrix 
metalloproteinase-9 (MMP-9) increase in DMPA users, 
while the activity of Tissue Inhibitory Metalloproteinase 
(TIMP) reduced. These events lead to weakening the 
supportive tissue around the vascular under the epithelial, 
hence the endometrial layer becomes fragile and the 
vascular is damaged. Therefore, bleeding occurs.8,9,10 
 Intervention that effectively controlled AUB will 
improve the continuation rate.8,11,12 The strategies for 
managing the bleeding that disturb DMPA users include 
combined oral contraceptive pills (OCP).11 If AUB still 
occurred while the patients is on OCPs, the next step is 
increasing the dosage of estrogen in OCP. OCP itself can 
reduce the bleeding about 34.9 %. The highest success 
rate to reduce AUB is insertion of Levonorgestrel 
Intrauterine Device (LNG-IUD) which can reduce the 
bleeding about 87%, but the weakness of this IUD are 
low acceptance and high cost, so clinician frequently add 
tranexamic acid (TXA) in DMPA users with 
AUB.13Endometrial fibrinolytic enzymes have important 
role in menstrual bleeding hemostatic, in AUB, plasmin 
activity and plasminogen activator increase, that will lead 
to the bleeding.14,1 TXA is widely known as 
antifibrinolytic,15 and commonly used to reduce heavy 
menstrual bleeding by reducing fibrin degradation in 
endometrial layer, which is expected to increase the 
effectivity of low dose OCP in managing the bleeding to 
improve the continuation rate of DMPA.  Unfortunately, 
we do not have data about the effect of TXA and OCP on 
bleeding length due to DMPA. So the aim of this study is 
to explore the effect of TXA on bleeding length for 
DMPA users who receive low dose OCP.  
 
MATERIALS AND METHOD 
 This double-blind randomized controlled trial was 
conducted in dr. Kariadi General Hospital in Semarang, 
Indonesia from October 2016 to August 2017. The 
participants were women using DMPA with AUB. 
 Inclusion criteria were being a new DMPA users, age 
20-45 years old, and a normal pelvic examination. 
Exclusion criteria were applied if the subjects had a 
gynecological disease that causes abnormal uterine 
bleeding, had a medical disease with bleeding tendency, 
allergic to TXA, contraindication to OCP and TXA and 
had a history of liver impairment and renal insufficiency. 
 AUB in this study was defined as bleeding or spotting 
for eight or more days in a month, which is appropriate 
with FIGO classification for prolonged AUB (which is 
more than 8 days).7 Before the study started, each subject 
was asked to read and sign informed consent. Written 
informed consent was obtained from the participants of 
the study and patients have a right and privacy to join the 
study and they can resign from the study anytime they 
want. We informed that OCP only is good enough in 
reducing the bleeding for about 34.9 %, and this study 
aim to know whether TXA can enhance the effect of OCP 
in reducing bleeding length in DMPA users. TXA is 
widely known as antifibrinolytic, and commonly used to 
reduce heavy menstrual bleeding by reducing fibrin 
degradation in endometrial layer, which is expected to 
increase the effectivity of low dose OCP in managing the 
bleeding to improve the continuation rate of DMPA. 
 Forty-four subjects in this study were divided with 
simple randomization into two groups, twenty-two 
subjects each. The first group received low dose OCP and 
TXA, while the second group received placebo and low 
dose OCP. The drugs for both groups were packaged in 
same colored capsules, we also asked people outside of 
author and co-author to choose a closed envelope 
containing which group the subjects would be assigned 
to. Both authors and subjects were not aware of the 
administered drugs.  
 Written informed consent was obtained from the 
participants of the study and patients have a right and 
privacy to join the study and they can resign from the 
study anytime they want. We informed that OCP only is 
good enough in reducing the bleeding for about 34.9 %, 
and this study aim to know whether TXA can enhance the 
effect of OCP in reducing bleeding length in DMPA 
users. 
 The dose of TXA was 250 mg. Both TXA and 
placebo were administered four times a day for 5 day (as 
previous study by Senthong A and Taneepanichskul), 
although according to our local consensus the 
recommended dose of TXA for AUB is 1 g three times 
daily. Both groups also received low dose OCP, 
containing 30 mcg ethinylestradiol and 150 mg 
levonorgestrel (Microgynon®), Bayer Schering Pharma, 
Berlin, Germany) to be administered once a day for 28 
days. Each subject received a card for documenting 
vaginal bleeding and side effect during the medication. 
The obtained data were analyzed. The difference of 
bleeding length between the two groups during the 
treatment was analyzed by a non-paired t-test for normal 
data distribution or Mann Whitney test for not normal 
data distribution.  Data were analyzed by SPSS for 
windows version 15.0 (SPSS Inc, USA). The data were 
considered significant if p value<0.05. 
 This study was approved by the Ethics Committee of 
Faculty of Medicine Diponegoro University and dr. 
Kariadi Hospital number 936/EC/FK-RSDK/IX/2016 
and was conducted according to the Declaration of 
Helsinki. 
 
RESULTS  
 There were 44 subjects; which then randomly 
assigned to 2 groups of treatment. Group 1 consist of 22 
women who received once-daily OCP for 28 days and 
TXA 250 mg, four-time daily for five days, and group 2 
consist of 22 women who received once daily OCP for 
28 days and placebo four-time daily for five days.  Until 
the end of the study no subject resigned, all of the 44 
women fill the menstrual card as shown in the Consort 
Diagram of Figure 1. 
 Table 1 showed characteristics of subjects, there was 
no significant difference of those characteristics (age, 
BMI, and number of previous pregnancies) between both 
groups. Therefore, those characteristics did not affect the 
study results.  
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P=0.018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The mean bleeding length during the treatment was 
significantly different between Group 1 and Group 2 
which is 5.2±3.62 days (1-11 days) and 9.2±6.16 days 
(2-23 days), respectively (p=0.018). The subjects given 
TXA and OCP had shorter bleeding days during 
treatment significantly compared with given OCP pills 
only as shown in figure 2. 
  
The percentage of subjects in whom bleeding was 
stopped during the first week after initial treatment was 
significantly higher in group 1 than group 2 (77.3 % VS 
45.5 %, p<0.050). 
 The side effects reported in this study were dizziness 
and nausea. Table 2 showed that five subjects in Group 
1 experienced the side effects, while only one subject in 
Group 2 experience them. The side effects were not 
significantly different between both groups (p = 0.185). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Bleeding length box plot between the two groups 
DISCUSSION  
 From our study result, we found that the mean 
bleeding length was 5.2±3.62 days and 9.2±6.16 days in 
groups 1 (TXA and low dose OCP) and 2 (OCP only) 
respectively. These bleeding lengths were significantly 
different between both groups (p=0.018). The 
percentage of subjects in whom bleeding was stopped 
during the first week after initial treatment was 
significantly higher in group 1 than group 2 (77.3 % VS 
45.5 %, p<0.050). 
46 subjects with 
AUB-I 
Exclusion criteria 
1 subject excluded because cardiac 
abnormality, 1subject excluded because 
gynecology abnormality 
44 subjects who meet 
the inclusion criteria 
Simple 
randomization and 
blinding 
Group 1 (22 subjects) 
TXA 4 x 250 mg (5 days) 
and low dose OCP once daily 
(28 days) 
Group 2 (22 subjects) 
Placebo 4 times daily (5 days) 
and low dose OCP once daily 
(28 days) 
Controlled by 
menstrual card 
Calculate number of 
bleeding days during 
medication 
Calculate number of 
bleeding days during 
medication 
Result analysis and reporting 
Table 1. Characteristics of subjects in both groups 
Characteristics 
 
Group 
P Group 1 
(n = 22) 
Group 2 
(n = 22) 
Age  31 26 0.086a 
Body Mass 
Index  
19.92 20.59 0.716a 
Number of 
previous 
pregnancies  
  0.067b 
1 (n (%))  7 (31.8) 15 (68.2)  
2 (n (%))  11 (50) 5 (22.7)  
3 (n (%))  2 (9.1) 2 (9.1)  
4 (n (%))  2 (9.1) 0 (0)  
SD = Standard Deviation 
 a) Mann Whitney; b) χ2 
Figure 1. Consort diagram 
 
Table 2. Side Effect in both groups 
Variable 
Group  
p Group 1 
n = 22 
Group 2 
n = 22 
Side effect    
Yes (n (%)) 5 (22.7) 1 (4.5) 0.185¥ 
No (n (%)) 17 (77.3) 21 (95.5)  
* Significant; § Mann Whitney; ¥ χ2 
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 In our study, the bleeding length was shorter 
significantly in Group 1 (TXA and low dose OCP). 
Several studies showed similar results that the use of 
TXA would shorten the bleeding length, especially for 
irregular bleeding. Senthong and Taneepanichskul 
found significant effect of TXA on AUB in DMPA 
users with the same dose, 250 mg TXA, four times a day 
for 5 days.16 Phupong et al. found a significant effect of 
the antifibrinolytic drugs in Norplant users who 
experienced irregular bleeding. The dose of TXA was 
500 mg, twice a day, for 5 days. The bleeding length 
was found to stop in less than 7 days in the treatment 
group.17Senthong et al also found a similar result when 
studying the effect of TXA in DMPA users compared 
with the placebo. In their study, the bleeding length of 
less than 1 week was found significantly higher in the 
treatment group (88% vs 8.2%). The mean of days 
without bleeding was also higher in treatment group 
(20.6 days) than the control group (7.5) days. In this 
study, the percentage of subjects in whom bleeding was 
stopped during the first week after initial treatment was 
significantly higher in the group  treated with TXA and 
OCP than OCP only (77.3 % VS 45.5 %, p<0.050).16 
 Mechanism of action of TXA is blocking lysin, the 
binding site of plasminogen reversibly, leading to 
inhibition of interaction between plasmin and fibrin 
polymer. Afterwards, TXA will reduce fibrin 
degradation, stabilize blood clot and reduce bleeding. 
Therefore, TXA acts effectively as a treatment for 
irregular bleeding caused by DMPA who had irregular 
bleeding due to hemostatic disturbance.17,14 The 
fibrinolytic enzymes in the endometrial layer have a 
significant role in the homeostasis of menstrual 
bleeding. In dysfunctional bleeding, the activity of 
plasmin and plasminogen activator increases due to an 
increase of fibrinolysis. TXA will exert its 
antifibrinolytic effects and reduce hypermenorrhea up 
to 50%.1The mild side effects, such as dizziness and 
nausea, were experienced by five subjects in Group 1 
(TXA and OCP) and one subject in group 2 (OCP only). 
Similar side effects were experienced by subjects 
treated with TXA in the study by Senthong et al.16 
 Risk factors, such as age, number of previous 
pregnancies, and BMI, were not significantly different 
between Group 1 and Group 2. Therefore, the bleeding 
length in both groups was not affected by those risk 
factors.18,19Similar result was shown by Senthong et al., 
with mean age of 27 and 29 years old in treatment and 
control group, respectively. Furthermore, they also 
found no significant effect of BMI and the number of 
previous pregnancies on the bleeding length.20 
 Limitations of this study were the short duration of 
the study and no data on hormonal levels, which are 
supposed to affect the bleeding length. Statistical 
analysis of the bleeding length before the treatment was 
also not performed. In conclusion, this study resulted in 
the reduction of bleeding length in DMPA users with 
administration of TXA. Further studies should be 
conducted with a longer duration (follow-up in 3 
months). 
 
 
 
 
CONCLUSIONS   
 The administration of TXA 250 mg four times daily 
for five days significantly reduces the bleeding length in 
DMPA users with AUB who use OCP. TXA can be used 
as alternative therapy to enhance the OCP effectivity for 
AUB due to DMPA. 
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